885115-45-7Relevant academic research and scientific papers
Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of β-secretase
Barrow, James C.,Stauffer, Shaun R.,Rittle, Kenneth E.,Ngo, Phung L.,Yang, ZhiQiang,Selnick, Harold G.,Graham, Samuel L.,Munshi, Sanjeev,McGaughey, Georgia B.,Holloway, M. Katharine,Simon, Adam J.,Price, Eric A.,Sankaranarayanan, Sethu,Colussi, Dennis,Tugusheva, Katherine,Lai, Ming-Tain,Espeseth, Amy S.,Xu, Min,Huang, Qian,Wolfe, Abigail,Pietrak, Beth,Zuck, Paul,Levorse, Dorothy A.,Hazuda, Daria,Vacca, Joseph P.
supporting information; experimental part, p. 6259 - 6262 (2009/10/17)
A high-throughput screen at 100 μM inhibitor concentration for the BACE-1 enzyme revealed a novel spiropiperidine iminohydantoin aspartyl protease inhibitor template. An X-ray cocrystal structure with BACE-1 revealed a novel mode of binding whereby the in
SPIROPIPERIDINE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHERMER’S DISEASE
-
Page/Page column 52-53, (2010/11/08)
The present invention is directed to spiropiperidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. T
